RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
David Koschut(Nanyang Technological University), Dean Nižetić(Queen Mary University of London)
Cited by 15
Related Papers
Mechanical Stress Induces a Transient Suppression of Cytokine Secretion in Astrocytes Assessed at the Single‐Cell Level with a High‐Throughput Microfluidic Chip
|Advanced Healthcare Materials|2021|13
RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutations
|bioRxiv (Cold Spring Harbor Laboratory)|2020|0